BMI Taiwan Pharmaceuticals and Healthcare Report Q1 2012.pdf
《BMI Taiwan Pharmaceuticals and Healthcare Report Q1 2012.pdf》由会员分享,可在线阅读,更多相关《BMI Taiwan Pharmaceuticals and Healthcare Report Q1 2012.pdf(113页珍藏版)》请在三一文库上搜索。
1、Q1 2012 pharmaceuticals +4.7% in local currency terms and +13.3% in US dollar terms. Broadly in line with our forecast. ? Healthcare: TWD759bn (US$24.12bn) in 2010 to TWD783bn (US$26.9bn) in 2011; +3.2% in local currency terms and +11.7% in US dollar terms. Broadly in line with our forecast. ? Medi
2、cal devices: TWD46bn (US$1.47bn) in 2010 to TWD49bn (US$1.70bn) in 2011; +6.5% in local currency terms and +15.3% in US dollar terms. Broadly in line with our forecast. Business Environment Rating: Taiwan experienced a 2.43% decrease in its Business Environment Rating (BER) from 61.7 in Q411 to 60.2
3、 in Q112. This decrease was due to a decline in its Industry Rewards score, which rose from 57 to 53 as we forecast a slower pharmaceutical sales compound annual growth rate (CAGR) of 3.9% in the medium term. In contrast, Singapore (fifth) which was ranked above Taiwan (sixth) is expected to have a
4、CAGR of 4.7%. Key Trends over the medium term (2010-2015) BMI project compound annual growth rate (CAGR) of 3.9% in local currency terms (6.5% in US dollars terms) for Taiwan. In contrast, the projected CAGR for Singapore is 4.7% in local currency terms, 9.3% in US dollars term. Taiwan Pharmaceutica
5、ls the Bureau of Pharmaceutical Affairs (BoPA) the former director of which has criticised the TFDA for cutting manpower, and for raising food and drug safety concerns; the National Laboratories of Foods and Drugs; and the National Bureau of Controlled Drugs, under the Cabinet-level Department of He
6、alth (DOH), which will remain in charge of drug testing and of post-good manufacturing practice (GMP) inspection. The TFDA will be assigned the development of drug production standards and regulations in line with international norms followed in other countries in the region, including China, Japan
7、and South Korea. The move will enable the country to introduce its biotech sector onto the international market and enhance the marketability of Taiwanese products. The new regulator is also expected to approve pharmaceuticals and medical devices more swiftly. In 2006, the approval time for new drug
8、s in Taiwan was calculated at an average of 30.5 months. Previously, product licences were issued in the name of the Department of Health, with the Bureau of Pharmaceutical Affairs (BPA) regulating the sector. The BPA was assisted in its evaluations by a non- governmental organisation, the Center fo
9、r Drug Evaluation (CDE), which is responsible for new drug application (NDA) approvals. The task had previously been partly handled by the Drug Review Board (DRB), which in 2007 became a consulting organisation. The changes had been initiated in order to reduce approval times, although they were onl
10、y partly successful. The recent introduction of the Health Technology Assessment (HTA) system for new drugs has negated some of the gains achieved by the CDE, given the increased research and administrative demand on drugmakers submitting files for approval. Prior to evidence evaluation, the propose
11、d price of a new pharmaceutical is benchmarked using existing prices in 10 other markets, presumably some more developed, such as Japan, and some less so, for example the Philippines, with prices then adjusted depending on efficacy. Additionally, BMI cautions that similar bodies in other countries h
12、ave been accused of delaying the introduction of innovative medicines. Taiwan Pharmaceuticals and ? Taiwan has yet to implement patent linkage in its regulatory procedures for approving generic drugs. Taiwan Pharmaceuticals regulations which are expected to affect 5,000 companies. ? In July 2010, th
13、e DOH in Taiwan set an upper limit on hospital registration fees in the country, reported the Central News Agency. The upper limit for outpatient clinic registration fees has been set at TWD150 (US$4.67), while that for accident and emergency (A foreign: 9,900). As the reclassification template was
14、based on the one used by the US FDA, medical devices made in the US are exempt from being required to submit quality system accreditation if the following documents are included in the submission: establishment inspection report, certification to foreign government and the ISO 13485 permit. Accordin
15、gly, US products (67%) account for a disproportionate slice of the Taiwanese medical equipment sector compared to products made in the rest of the world (28%). Other barriers to entry include not insignificant import duties (5-7.5%) and the open bid hospital tender, which can be challenging. An expe
16、rienced local distributor is a must as Taiwanese customers are highly influenced by relationships with their suppliers. In recent years, China has begun viewing Taiwan as one of the more interesting export destinations for its medical devices. The countrys highly efficient reimbursement system has b
17、een cited as one of the main attractions to market penetration. Administration costs incurred by the national healthcare insurance scheme are less than 2% of total expenditure, which compares favourably to other developed states. For example, running costs for the UKs National Health Service (NHS) a
18、re approaching 10% of overall spending. This means that more funds in Taiwan are allocated to innovative and invariably expensive products. In fact, according to director general of the Industrial Development Bureau, the medical devices industry in Taiwan has been the fastest-growing domestic biotec
19、h industry segment in the past five years. The government is actively promoting the sector, especially medical electronics, its largest component (at 60% of the total). According to ITRI data, in 2007, turnover in the Taiwan medical equipment industry totalled US$74.9bn. While presently only account
20、ing for around 1% of the global market share, the industry is growing at around 16.5%, above the average global rate. Leading local companies include Taiwan Pharmaceuticals Sources: 2 National Statistics Of Taiwan, BMI; 3 BMI calculation; 4 Central Bank of the Republic of China, BMI; 5 DGBAS, BMI. T
21、aiwan Pharmaceuticals Everlight, a bulk pharmaceutical producer; and Standard, which produces medicines, pharmaceutical raw materials, diagnostic kits and Chinese medicines. Although the Taiwanese drug market is small and heavily reliant on imported drugs, foreign drugmakers are widely represented o
22、n the island through direct manufacturing facilities. Most major multinationals have a presence in Taiwan, including GSK, Pfizer, Merck a pharmaceutical composition for an anti-ulcer drug; the matrix controlled-release system; a pharmaceutical composition for an anti-coagulant; and novel drug- deliv
23、ery systems for transdermal preparations for terazosin HCl and sub-lingual preparations for neostigmine bromide. In order to actively expand business inside and outside Taiwan, Empax founded its headquarters in Nei- Hu Technology Park in Taipei April 2002, and also in Tien-He high tech Park in Guang
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- BMI Taiwan Pharmaceuticals and Healthcare Report Q1 2012
链接地址:https://www.31doc.com/p-3730289.html